EUVIMEDEUVIMED entdecken
Crossref

LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results

José Silva Cardoso

European Journal of Arrhythmia & Electrophysiology · 2016

DOI: 10.17925/ejae.2016.02.01.14 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Arrhythmia & Electrophysiology, 2016. Verfasst von José Silva Cardoso. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This editorial summarises important findings from the PARADIGM-HF study. PARADIGM-HF indicated that the angiotensin receptorneprilysin inhibitor, LCZ696, is superior to enalapril in reducing the risks of cardiovascular death and of hospitalisation for heart failure in patients with heart failure and reduced ejection fraction.

Zitieren

APA

Cardoso, J. S. (2016). LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results. European Journal of Arrhythmia & Electrophysiology. https://doi.org/10.17925/ejae.2016.02.01.14

Vancouver

Cardoso JS. LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results. European Journal of Arrhythmia & Electrophysiology. 2016. doi:10.17925/ejae.2016.02.01.14

BibTeX
@article{Cardoso2016,
  author = {Cardoso, José Silva},
  title = {LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results},
  journal = {European Journal of Arrhythmia & Electrophysiology},
  year = {2016},
  doi = {10.17925/ejae.2016.02.01.14}
}
Kostenlos starten →